Avanir Pharmaceuticals (AVNR) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Financial Fact:
Total operating expenses: 40.52M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Total operating expenses: 40.52M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $28.21 million.
For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Vivos Therapeutics posts 35% revenue gain but widens net loss
- Reading (RDI) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
